secwatch.observer — SEC 8-K summary
======================================

Issuer:     IMMUCELL CORP /DE/ (ICCC)
CIK:        0000811641
Form:       8-K
Filed at:   2026-01-08T23:59:59+00:00
Accession:  0001437749-26-000885
Event type: earnings
Sentiment:  negative
Materiality: 0.80
Item codes: 2.02, 2.06, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

ImmuCell reports Q4 sales down 1.6% YoY; records $3.6M impairment, pauses Re-Tain
--------------------------------------------------------------------------------

- Q4 total sales $7.6M (-1.6% YoY); domestic sales up 8.7%, international down 52.6%.
- FY 2025 total sales $27.6M (+4.3% YoY); Tri-Shield sales $19.9M (+26.5%), Dual-Force $6.9M (-27.4%).
- Records $3.6M non-cash impairment: $2.9M Re-Tain PPE, $0.1M other PPE, $0.6M colostrum inventory write-down.
- Pausing Re-Tain investment after FDA Incomplete Letter; repurposing $15.5M Re-Tain assets for First Defense.
- Tri-Shield sales exceed expectations; expanding sales force by 50% with new U.S. territories and international hire.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/811641/000143774926000885/0001437749-26-000885-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/811641/000143774926000885/iccc20260108_8k.htm
  HTML page:      https://secwatch.observer/filing/0001437749-26-000885

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer